Lilly Aims For Earlier Treatment With Novel Diabetes Drugs

GLP-1/GIP Agonist Tirzepatide Leads Next-Gen Pipeline

 
• By Mandy Jackson
  
Diabetes; Chalkboard on a wooden background
Lilly is looking beyond diabetes to obesity, NASH and heart failure with its incretin agonists • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

More from Therapeutic Category